Determining class II human leukocyte antigens to identify potential disease association and as markers for drug hypersensitivity
2DIS
Whole Blood ACD
Container/Tube: Yellow top (ACD solution A or B)
Specimen Volume: 6 mL
Collection Instructions: Send whole blood in original tube. Do not aliquot.
Additional Information: Specimen acceptability is based on extracted DNA concentration and not sample age.
If not ordering electronically, complete, print, and send a Hematopathology/Cytogenetics Test Request (T726)) with the specimen.
3 mL
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Whole Blood ACD | Ambient (preferred) | ||
Refrigerated |
Determining class II human leukocyte antigens to identify potential disease association and as markers for drug hypersensitivity
Human leukocyte antigen (HLA) class II genes (HLA-DRB1, -DRB3/4/5, -DQA1, -DQB1, -DPA1, -DPB1) are a part of the major histocompatibility gene complex that encodes for proteins involved in immune recognition.
This assay is designed to provide low-to-medium resolution for HLA class II typing. Low-to-medium resolution defines the typing at first field (antigen or allele group level). This contrasts with high-resolution typing, which defines typing at second field or higher (allele level).
Not applicable
Interpretation depends on the rationale for ordering the test.
No significant cautionary statements.
1. Terasaki PI, Bernoco D, Park MS, Ozturk G, Iwaki Y: Microdroplet testing for HLA-A, B, C and D antigens. Am J Clin Pathol. 1978 Feb;69(2):103-120
2. Colinas RJ, Bellisario R, Pass KA: Multiplexed genotyping of beta-globin variants form PCR-amplified newborn blood spot DNA by hybridization with allele-specific oligodeoxynucleotides coupled to an array of fluorescent microspheres. Clin Chem. 2000 Jul;46(7):996-998
3. Kennedy AE, Ozbek U, Dorak MT: What has GWAS done for HLA and disease associations? Int J Immunogenet. 2017 Oct;44(5):195-211. doi: 10.1111/iji.12332
4. Caillat-Zucman S: New insights into the understanding of MHC associations with immune-mediated disorders. HLA. 2017 Jan;89(1):3-13. doi: 10.1111/tan.12947
5. Howell WM: HLA and disease: guilt by assocation. Int J Immunogenet. 2014 Feb;41(1):1-12. doi: 10.1111/iji.12088
6. Profaizer T, Pole A, Monds C, Delgado JC, Lazar-Molnar E: Clinical utility of next generation sequencing based HLA typing for disease association and pharmacogenetic testing. Hum Immunol. 2020 Jul;81(7): 354-360
For resolution of an allelic ambiguity or in select cases, the following additional methodologies may be utilized:
-Sequence-based typing (SBT) by Sanger sequencing(Package insert: SeCore Sequencing and GSSP Kits. One Lambda, Inc; Rev 3, 02/06/2021)
-SBT by sequence-specific primers (SSP)(Package insert: Olerup SSP HLA typing kits including Taq Polymerase. CareDx; Rev 04, 12/2020)
-SBT by next-generation sequencing (NGS)(Package inserts: Holotype HLA Kit. Omixon; v3.0.1, 08/16/2019; NGSgo HLA Kit. GenDx; v2, 02/2021)
Monday
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.
81375
81376 (as appropriate)
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
2DIS | HLA-DR-DQ DisAssoc Typing LowRes,B | 96640-8 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
LRTMB | Test Method | 85069-3 |
2DA02 | DRDQ DisAssoc Comment | 96625-9 |
2DA03 | DRB1 - 1 Equivalent | 57298-2 |
2DA04 | DRB1 - 2 Equivalent | 57298-2 |
2DA05 | DRB1 - 1 Molecular | 96664-8 |
2DA06 | DRB1 - 2 Molecular | 96664-8 |
2DA07 | DRB345 - 1 Equivalent | 96673-9 |
2DA08 | DRB345 - 2 Equivalent | 96673-9 |
2DA09 | DRB345 - 1 Molecular | 96672-1 |
2DA10 | DRB345 - 2 Molecular | 96672-1 |
2DA11 | DQB1 - 1 Equivalent | 53938-7 |
2DA12 | DQB1 - 2 Equivalent | 53938-7 |
2DA13 | DQB1 - 1 Molecular | 78017-1 |
2DA14 | DQB1 - 2 Molecular | 78017-1 |
2DA15 | DQA1 - 1 Molecular | 96654-9 |
2DA16 | DQA1 - 2 Molecular | 96654-9 |
2DA17 | DPB1 - 1 Molecular | 96648-1 |
2DA18 | DPB1 - 2 Molecular | 96648-1 |
2DA19 | DPA1 - 1 Molecular | 96643-2 |
2DA20 | DPA1 - 2 Molecular | 96643-2 |
LRTM2 | Test Method | 85069-3 |
Change Type | Effective Date |
---|---|
Test Changes - Method | 2022-03-24 |